Gyre Therapeutics (GYRE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

GYRE Gyre Therapeutics

Watchlist

10.790
-3.180-22.76%

Close Aug 2 16:00 ET

10.600
-0.190-1.76%

Post 20:02 ET

922.65MMarket Cap-10516P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Gyre Therapeutics Seeks Compliance Amid Board Reshuffle
TipRanksJul 5 17:18 ET
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
BenzingaJul 5 12:47 ET
Express News | Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia
BenzingaJul 5 12:47 ET
Gyre Therapeutics Low Blood Platelet Treatment Approved in China
MT NewswiresJul 2 16:25 ET
Express News | Gyre Therapeutics Reports China's NMPA Approval Of Avatrombopag Maleate Tablets For Treatment Of CLD-Associated Thrombocytopenia
BenzingaJul 2 16:06 ET
Express News | Gyre Therapeutics Announces China’s Nmpa Approval of Avatrombopag Maleate Tablets for the Treatment of Cld-Associated Thrombocytopenia
ReutersJul 2 16:05 ET

Comments

108S

Jul 16 18:53

$Gyre Therapeutics(GYRE.US)$ sell or hold?

Jaguar8

May 30 15:11

NEWS

$Gyre Therapeutics(GYRE.US)$
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics (Nasdaq: GYRE), a biotech firm specializing in anti-fibrotic treatments, has received approval from China's NMPA for its Investigational New Drug (IND) application for F230. This drug, a selective endothelin receptor antagonist, is aimed at treating pulmonary arterial hypertension (PAH), a severe and progressive diso...

108S

May 29 08:33

$Gyre Therapeutics(GYRE.US)$Gyre Therapeutics Expects Addition To Russell - moomoo

Moomoo Recap US

Jan 22 15:13

Columns Wall Street Street | Great Day For Volume Stocks on Fresh Index Records

RECAP
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average(.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index(.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index(.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...

Kevin Travers

Jan 22 09:51

Columns BiotTech Rises with the Index Tide

After two major indexes reached all-time highs, pharmaceutical stocks for companies in drug trials were caught up in the energy and rocketed forward. The largest gainers were $Spyre Therapeutics(SYRE.US)$, up 26% Monday morning, and $Gyre Therapeutics(GYRE.US)$ +10%.
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks(DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

GYRE Gyre Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target